For the first time, Australians with schizophrenia will have access to the antipsychotic Reagila® (cariprazine). Schizophrenia is a serious mental health condition with a wide range of symptoms and affects about 1 in 100 people.
A third PDA, cariprazine, has now become available in Australia. It was listed on the PBS for the treatment of schizophrenia in September 2021. This article describes the features of cariprazine and its potential role in the treatment of patients with schizophrenia.
Lumateperone (Caplyta, Intra-Cellular Therapies) is a new antipsychotic medication, approved by the Food and Drug Administration (FDA) in 2019 for adults with schizophrenia and approved in 2021 for adults with depressive episodes associated with bipolar I or II disorder.
Clozapine, which has the strongest antipsychotic effect, can cause neutropenia.
Some newer atypical antipsychotics include asenapine (Saphris), iloperidone (Fanapt) and lurasidone (Latuda). Atypical antipsychotics have largely replaced traditional agents as first-line therapy in the treatment of schizophrenia.
Quetiapine is the least likely to cause extrapyramidal side effects. The most common side effects of quetiapine are somnolence, orthostatic hypotension, and dizziness. Ziprasidone has almost no weight gain but can cause prolongation of QTc.
The US Food and Drug Administration (FDA) has approved UZEDY, a new drug for the treatment of schizophrenia.
Based on SUCRA ranking, olanzapine and quetiapine ranked the best tolerated treatments in terms of all-cause discontinuation followed by cariprazine, lurasidone, ziprasidone and aripiprazole (Table 14).
Studies state that Seroquel is the most abused atypical antipsychotic. It's believed that people abuse and misuse Seroquel because of how it reduces anxiety and ease sleep deprivation, not because of its euphoric effects.
The main study findings, from this population-wide head-to-head comparison of thirty-seven antipsychotics, is that zuclopenthixol showed the strongest association with sedation and somnolence while prochloperazine resulted in the weakest association.
Reviva, Newron, and Sunovion target total symptoms
In mid-2023, Reviva expects topline results for the 402-patient Phase III RECOVER trial of brilaroxazine in schizophrenia (NCT05184335). Brilaroxazine is a dopamine-serotonin stabilizer, meaning it acts on both dopamine and serotonin receptors.
The FDA cleared Teva Pharmaceuticalsand MedinCell's Uzedy (risperidone) extended-release injectable suspension, the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq™, a copolymer technology proprietary to MedinCell that controls the steady release of risperidone, the pharma makers said ...
Sublingual dexmedetomidine (Igalmi) was approved last year for acute agitation in adult patients with schizophrenia or bipolar I or II disorder. Keep a look out for these medications, as xanomeline-trospium will be coming in 2023 and lumateperone, Rykindo, and Igalmi have been FDA-approved within the past year.
Mood stabilisers, including lithium and anticonvulsants such as carbamazepine have been proposed as an alternative therapy to standard antipsychotic treatments when individuals have sub-optimal responses to treatment.
Last December, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the antipsychotic Caplyta (lumateperone) for the treatment of bipolar I and II depression in adults. Caplyta, marketed by Intra-Cellular Therapies Inc., was already approved for the treatment of schizophrenia in adults.
Antipsychotics were discovered in the late 1950s. This first antipsychotic drug, chlorpromazine, was first developed as a “tranquilizer.” Its usefulness for treating psychosis was recognized by accident. It was found to decrease positive symptoms such as hallucinations, delusions, and thought disorder.
Clozapine is the only FDA-approved medication for treatment-resistant schizophrenia. It treats symptoms of psychosis like hallucinations and delusions. It also improves mood and behavior.
Tardive dyskinesia (TD) is a side effect of certain medications, mainly antipsychotics. It involves experiencing sudden, jerky or slow twisting movements in your face or body.
Of the atypical antipsychotics, risperidone is the weakest in terms of atypicality criteria.
Atypical antipsychotics such as quetiapine, aripiprazole, olanzapine, and risperidone have been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and have since been used in the treatment of a range of mood and anxiety disorders ...
But clozapine is uniquely effective in its ability to improve clinical outcomes in patients with treatment resistance schizophrenia.
Drugs with the fastest onsets include haloperidol, risperidone, and olanzapine, with onsets appearing in 2 6 days. Chlorpromazine and thiothixene were at the slowest end of the continuum, with onsets of 2 weeks or longer.